Prescription Drugs

Prescription Drugs
Author: United States. General Accounting Office
Publisher:
Total Pages: 40
Release: 1991
Genre: Advertising
ISBN:

Making Medicines Affordable

Making Medicines Affordable
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Total Pages: 235
Release: 2018-03-01
Genre: Medical
ISBN: 0309468086

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

Prescription Drugs

Prescription Drugs
Author: United States. General Accounting Office
Publisher:
Total Pages: 24
Release: 1991
Genre: Advertising
ISBN:

Selling Sickness

Selling Sickness
Author: Ray Moynihan
Publisher: Greystone Books
Total Pages: 171
Release: 2008-09-01
Genre: Health & Fitness
ISBN: 1926706684

In this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.

Prescription Drugs

Prescription Drugs
Author: U S Government Accountability Office (G
Publisher: BiblioGov
Total Pages: 44
Release: 2013-06
Genre:
ISBN: 9781289088880

Pursuant to a congressional request, GAO reviewed direct-to-consumer advertising (DTCA) of prescription drugs, focusing on: (1) its potential benefits or detriments; (2) consumer and physician attitudes toward DTCA and the confidence placed in this knowledge; and (3) existing research gaps regarding DTCA. GAO found that: (1) the many benefits cited as possible effects of DTCA included consumer education, price reduction, and patient involvement in health care, and the detriments included physician shopping, increased costs, and inadequate risk information; (2) the findings from the few studies conducted to determine the possible effects of DTCA did not apply to all types of advertising or to all consumers; (3) the few research studies of physicians' and consumers' opinions of DTCA were limited since the studies did not systematically address the advertising and media differences, and sampling designs were flawed; (4) as a result of the limitations, those studies did not measure the extent to which opinions about DTCA were positive or negative or short-term changes in those opinions; (5) studies indicated that, generally, physicians opposed DTCA because they believed that it would undermine the physician-patient relationship with the extent of their opposition depending on the type of DTCA, the media, and the content; (6) since most consumers were unaware of DTCA, they based their opinions about it on other experiences, such as other products' advertisements; (7) in general, consumers supported DTCA because they believed that it would provide them with information; (8) there was limited information regarding whether DTCA effects differed by media or content; and (9) such gaps as the effect of widespread advertising on drug prices may not be possible to study before the actual widespread implementation of DTCA.